Sustained Benefit with DIABECELL® Implants
Living Cell Technologies Reports Interim Results Showing Sustained Benefit with DIABECELL® Implants for Insulin Dependent Diabetes
February 11, 2009 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) reports positive interim results from the long term follow-up of insulin dependent diabetes patients in the Phase I/IIa clinical trial of its lead product, DIABECELL®.
A total of seven patients have received DIABECELL® implants, five of whom have had two low dose (5,000 islet equivalents (IEQs) per kg body weight) implants at least six months apart. There have been no remarkable adverse events attributed to double implants. Two patients have received a single higher dose (10,000 IEQs/kg) with no safety concerns to date.
The results of 36 to 68 weeks follow-up from the first four patients showed that good blood glucose control was maintained as reflected by a reduction in glycated hemoglogin (% HbA1c) levels from a mean of 8% pre-enrolment to 6.8% at time of clinical review. The American Diabetes Association target for good blood glucose control is HbA1c below 7% and the normal is less than 6.2%. This control was attained despite a reduction of 10% - 38% in the required daily insulin dose.
It is too early to assess the second implant for the fifth patient. However, the patient’s HbA1c improved markedly from 9.8% before enrolment to 7.2% accompanied with a small reduction in the average daily insulin dose of 6%.
LCT Medical Director, Professor Bob Elliott said, “The patients clearly benefited from the implants administered at the lowest dose. The second implant maintained this benefit. Remarkably none of the patients have had problems with clinically relevant episodes of low blood glucose. Most people with diabetes cannot attain this degree of blood glucose control shown by these patients without large swings of very low or high blood glucose levels that are often fatal.”
Two more patients have received the higher dose of DIABECELL®. Patient six declined further follow-up at 20 weeks after the first implant when there was no change in glucose control or insulin dose. To improve consistency, LCT narrowed product quality release specifications for all subsequent implants. Patient seven has been followed up for only four weeks at which time HbA1c improved dramatically from 8.3% to 4.8% and daily insulin requirement dropped by 60%.
Professor Elliott further stated, “We can expect better outcomes with higher doses. The encapsulated cells offer not only an alternative but a physiological replacement therapy to provide new hope and improved lifestyles for people with diabetes.”
Dr Paul Tan, LCT Chief Executive Officer, said, “The next three patients in Russia are scheduled to receive the 10,000 IEQ/kg dose by April this year before testing the top dose of 15,000 IEQs/kg. Steps to initiate a pivotal trial and a commercialization strategy in Russia have been taken.”
DIABECELL® is LCT’s encapsulated porcine insulin-producing cell product designed for the treatment of type 1 diabetes without the use of immunosuppressive drugs.
-Ends-
About Living Cell Technologies:
www.lctglobal.com
Living Cell Technologies (LCT) is
developing cell-based products to treat life threatening
human diseases. The Company owns a biocertified pig herd
that it uses as a source of cells for treating diabetes and
neurological disorders. For patients with type 1 diabetes,
the Company transplants microencapsulated islet cells so
that near-normal blood glucose levels may be achieved
without the need for administration of insulin or at
significantly reduced levels. The company entered clinical
trials for its diabetes product in 2007. For the treatment
of Huntington’s disease and other neurological disorders,
the company transplants microencapsulated choroid plexus
cells that deliver beneficial proteins and neurotrophic
factors to the brain. LCT’s technology enables healthy
living cells to be injected into patients to replace or
repair damaged tissue without requiring the use of
immunosuppressive drugs to prevent rejection. LCT also
offers medical-grade porcine-derived products for the repair
and replacement of damaged tissues, as well as for research
and other purposes.
LCT Disclaimer
This document
contains certain forward-looking statements, relating to
LCT’s business, which can be identified by the use of
forward-looking terminology such as “promising,”
“plans,” “anticipated,” “will”, “project”,
“believe”, “forecast”, “expected”,
“estimated”, “targeting”, “aiming”, “set
to,” “potential,” “seeking to,” “goal,”
“could provide,” “intends,” “is being
developed,” “could be,” “on track,” or similar
expressions, or by express or implied discussions regarding
potential filings or marketing approvals, or potential
future sales of product candidates. Such forward-looking
statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. There
can be no assurance that any existing or future regulatory
filings will satisfy the FDA’s and other health
authorities’ requirements regarding any one or more
product candidates nor can there be any assurance that such
product candidates will be approved by any health
authorities for sale in any market or that they will reach
any particular level of sales. In particular, management’s
expectations regarding the approval and commercialisation of
the product candidates could be affected by, among other
things, unexpected clinical trial results, including
additional analysis of existing clinical data, and new
clinical data; unexpected regulatory actions or delays, or
government regulation generally; our ability to obtain or
maintain patent or other proprietary intellectual property
protection; competition in general; government, industry,
and general public pricing pressures; and additional factors
that involve significant risks and uncertainties about our
products, product candidates, financial results and business
prospects. Should one or more of these risks or
uncertainties materialise, or should underlying assumptions
prove incorrect, actual results may vary materially from
those described herein as anticipated, believed, estimated
or expected. LCT is providing this information as of
December 2008 and does not assume any obligation to update
any forward-looking statements contained in this document as
a result of new information, future events or developments
or otherwise.